Funded Startups in Minnesota City
Among the eight Minnesota City entries, the only disclosed round above $20M is Minnesota Medical Technologies’ $21M Series A on 2026-03-05; the next-larges…
Among the eight Minnesota City entries, the only disclosed round above $20M is Minnesota Medical Technologies’ $21M Series A on 2026-03-05; the next-largest disclosed amount is $10M (Panbela Therapeutics, 2023-07-19), so the top round materially outweighs the rest. The list also shows cluster behavior: three disclosed rounds fall between 2023-05-11 and 2023-08-22 (Impacks $640K; Panbela Therapeutics $10M; Priority Courier Experts undisclosed), and two additional biotechnology/health-adjacent rounds appear in 2025–2026 (Insitu Biologics $4M on 2025-12-18; Minnesota Medical Technologies $21M on 2026-03-05). Sector-wise, biotechnology and health care together dominate, and stage disclosures are uneven, with “Series Unknown” and a blank stage appearing alongside one Seed and one Series A. Dates span 2020-06-25 (Cryosa, $8M) through 2026-03-05, with the most recent entry belonging to Minnesota Medical Technologies.
Most recent rounds
8 shownRelated listings
Frequently asked
What stands out in the disclosed funding sizes for Minnesota City, and is there a clear outlier?
Minnesota Medical Technologies’ $21M Series A (2026-03-05) is an outlier relative to the other disclosed amounts in this view; the next-highest disclosed figure is Panbela Therapeutics’ $10M (2023-07-19), with most other disclosed rounds at $8M or below (e.g., Cryosa $8M on 2020-06-25; Insitu Biologics $4M on 2025-12-18).
Do the most recent rounds cluster into a narrow window rather than spreading evenly across the date range?
Yes. Within 2023, three entries land close together: 2023-05-11 (Impacks $640K), 2023-07-19 (Panbela Therapeutics $10M), and 2023-08-22 (Priority Courier Experts, undisclosed). Outside 2023, another visible concentration occurs around 2025–2026 with Insitu Biologics on 2025-12-18 ($4M) followed by Minnesota Medical Technologies on 2026-03-05 ($21M).
How much of this Minnesota City list has undisclosed or unspecified round types versus named stages?
Named stages are limited: there is one Seed (Ambient Intelligence, $100K on 2024-07-09) and one Series A (Minnesota Medical Technologies, $21M on 2026-03-05). Five of the eight rows are “Series Unknown” (Insitu Biologics 2025-12-18 $4M; Priority Courier Experts 2023-08-22 undisclosed; Panbela Therapeutics 2023-07-19 $10M; Impacks 2023-05-11 $640K; Boon Logic 2021-03-04 $5M) and Cryosa (2020-06-25 $8M) has a blank stage classification.
Is the sector mix concentrated in a few categories for Minnesota City?
Biotechnology and health care dominate. Biotechnology appears in Insitu Biologics (2025-12-18, $4M), Panbela Therapeutics (2023-07-19, $10M), and Cryosa (2020-06-25, $8M); health care appears in Minnesota Medical Technologies (Series A, 2026-03-05, $21M), Ambient Intelligence (Seed, 2024-07-09, $100K), and also Insitu Biologics (health-related biotech). Other sectors (Administrative Services, Community and Lifestyle, and AI) each appear once or twice.
Which entries are most likely to be actionable for diligence based on being near the newest dates, and do those entries skew large or small?
The newest set is tightly timed: Minnesota Medical Technologies ($21M, 2026-03-05) and Insitu Biologics ($4M, 2025-12-18) are the two most recent disclosed rounds in this view. In contrast, the smallest disclosed amount is Ambient Intelligence’s $100K Seed (2024-07-09), which is far below the two newest disclosed figures, indicating a wide spread in round sizes even within the mid-to-late 2020s dates shown.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.